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Background: Pneumococcus is the leading cause of community acquired pneumonia (CAP) worldwide, and the leading 
cause of mortality. Pneumococcal pneumonia is poorly studied in Nigeria. We describe the epidemiology including 
associated co-morbidities and outcome of pneumococcal pneumonia in North-western Nigeria.  
Material and methods: We conducted a prospective, hospital based study on patients with community acquired 
pneumococcal pneumonia. Detailed clinical evaluation and relevant laboratory investigations were carried out. 
Susceptibility test to commonly used antibiotics was carried out on all confirmed pneumococcal isolates. In hospital 
mortality was recorded. Analysis was carried out using descriptive statistics with differences and relationships were 
determined using Chi square and Fisher’s exact tests as appropriate, with p < 0.05 regarded as significant.  
Results: Of the one hundred and twenty-five (125) patients with pneumococcal pneumonia were studied. The mean age of 
the patients was 41.3years (± 16.84), and 69/125(55.2%) were males.  Co-morbidities were observed in 63/125 (53.8%) of 
the patients. Resistance to commonly used antibiotics was observed. Overall in-hospital mortality was 9/117(7.8%). HIV 
(OR=2.081; 95%CI 1.651-3.237), age ≥65years (OR=5.947; 95%CI3.581-17.643), and CURB-65 score of ≥ 3 (OR=2.317; 
95%CI1.734-4.719) were independent predictors of mortality.  
Conclusion: Pneumococcal pneumonia is the commonest cause of CAP in North-western Nigeria with relatively high 
mortality. There is need to strengthened the vaccination policy targeting at risk adult population in Nigeria.  
 





Streptococcus pneumoniae (the pneumococcus) is the major cause of community-acquired pneumonia (CAP) and 
a large contributor to morbidity and mortality worldwide (Ortqvist et al., 2005). It is an important public health concern 
throughout the world and a leading cause of morbidity and mortality (WHO, 2005). Africa and Asia are among the ten (10) 
countries with the highest numbers of pneumococcal infection globally, and combined together they account for 66% of 
cases (O’Brien et al, 2009). Nigeria accounts for 5% of the total burden at the third place after India and China (WHO, 
2014). Studies from different part of Nigeria have shown that pneumococcus accounts for 50%, 54.5%, and 60% of CAP 
(Macfarlane et al., 1979; Nwosu et al., 1991; Musa et al., 2008).  No population-based data on pneumococcal disease in 
adults in developing countries are available; estimates of disease burden are based on small clinical studies, vaccine trials, 
extrapolation from data in developed countries, and studies of persons at high risk for disease. Community acquired 
pneumonia has been studied in detail in Nigeria; however, there is a paucity of data on pneumococcal pneumonia. The 
Human Immunodeficiency Virus (HIV) pandemic and emergence of pneumococcal resistance has furthered the need to 
study pneumococcal pneumonia in the context of co-morbidities and outcome. This study is set to describe the 
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Materials and Methods 
 
The study was a prospective study among 125 patients with community acquired pneumococcal pneumonia. The 
study was conducted in one of the major tertiary referral centres in north-western Nigeria over the period June 2009 to 
January 2011. The hospital has 550 beds and offers specialist inpatient and outpatient care, across various specialties.  
All adult patients who were admitted over the study period with features compatible with CAP were initially 
screened, and those with microbiologically confirmed pneumococcal pneumonia were finally recruited. A sputum specimen 
was collected in a clean, sterile container from all the patients. In addition, blood samples were also collected, and 
inoculated directly into each of Brain-Heart infusion and thioglycolate culture media, with the use of standard aseptic 
procedures for aerobic and anaerobic cultures, respectively.  All Samples were taken before administering antibiotic 
whenever feasible and transported to the laboratory immediately.  
The sputum specimens were inoculated onto 5% sheep blood agar and incubated at 37
o
C. Inoculated plates were 
incubated in a candle jar so as to create a reduced oxygen tension (5%-10% additional CO2 tension). Inoculated blood 
culture bottles were incubated in the laboratory at 37
0
C and observed for bacterial growth within 24 to 72hours and then 
until day 7 if there was no bacterial growth. Subcultures of inoculated media were done twice, on days 2 and 3 after 
incubation, and were inoculated onto blood agar plates and incubated as far sputum. Plates were examined after incubation 
for bacterial pathogens, by the use of standard procedures. Samples of all typical pneumococcal colonies obtained from the 
plates were subjected to pneumococcal identification methods of α-haemolysis, colony morphology and ethylhydrocupreine 
hydrochloride (optochin) sensitivity. (CLSI, 2006) All those with microbiologically proven pneumococcal infection were 
finally selected for the study.  
Microbial susceptibility tests were carried out on all confirmed pneumococcal isolate to Penicillin G, Amoxycillin, 
Cefuroxime, Azithromycin, Ceftriaxone and Trimethoprim/sulfamethoxazole(TPM/SMX), using Etest strips (Manufactured 
by AB BIODISK, Sweden). Minimum inhibitory concentrations (MICs) were measured and strains were divided into 
resistant, intermediate or sensitive according to the CLSI guidelines (CLSI, 2006).  
All the patients who consented were screen for HIV infection using double Enzyme Link Immunosorbent Assay (ELISA). 
(Rehle et al., 1997). 
 
Pneumococcal pneumonia was defined based on clinical findings plus a chest radiograph consistent with pneumonia, in 
addition to Gram positive diplococci on microscopy and positive culture of pneumococcus from an ideal sputum specimen 
defined as the presence of more than 25 white cells and less than 10 squamous epithelial cells per low power field.  
The following clinical data of all patients with bacteriologically proven pneumococcal pneumonia were collected 
and analyzed: demographic data, clinical presentation, co morbidities, HIV sero-status for those who consented, antibiotic 
susceptibility result and in-hospital mortality. All patients were managed according to the hospital’s standard protocol for 
CAP. (AKTH, 2009) 
Analysis was carried out using descriptive statistics with differences and relationships determined using Chi 
squared and Fisher’s exact tests as appropriate, with p < 0.05 regarded as significant. Predictors were explored using 
univariate and multivariable analysis with unadjusted (crude) odds ratio (OR) and logistic regression adjusted, respectively. 
Statistical Package for Social Sciences version 16.0 was used. 
Ethical clearance was obtained from the research and ethics committee of AKTH in 2009. Informed consent was 




Out of the 232 cases of bacteriologically proven community acquired pneumonia screened, 125/232(53.9%) had 
microbiologically proven pneumococcal pneumonia.  Out of the 125 patients; 7/125(5.6%) had bacteraemic pneumonia, 
while the remaining 118 had primary pneumococcal pneumonia. The ages of the patients ranged from 18-79 years, with a 
mean age of 41.3years (± 16.84). As indicated in Table 1. The peak age groups were   55-64 years and ≥65 years. There 
were 69/125(55.2%) males and 56/125(44.8%) females with a male to female ratio of 1.23. The highest number of cases 
seen 20/125 (16.0%) was in January; the lowest was in August through September which constitutes the peak of the rainy 
season while November to January is within the harmattan period. 
Sixty-three (53.8%) of the patients were found to have co-morbidity: chronic pulmonary disease (CPD) 22 
(34.9%), HIV 9 (14.2%), sickle cell anaemia 12 (19.4%), chronic liver disease (CLD) 5 (7.9%) and chronic heart disease 
(CHD) 10 (15.9%). Table 1 Of the 125 patients, 71/125(56.8%) consented for HIV screening, out of which 9/71 (12.7%) 
tested positive.  Out of the 125 patients, 20(16%) were smokers.  
Only 5 (3.8%) of the isolates were sensitive to TPM/SMX, while 19 (15.2%) and 121(96.8%) were fully sensitive 
to penicillin and ceftriaxone respectively. (Table 2) 
Eight patients were lost to follow-up and the overall mortality in the remaining 117patients was 9/117(7.8%). The highest 
mortality was in those aged ≥65years. Table 3: shows mortality by co-morbidities. Higher CURB-65 score was 
significantly associated with increased mortality. (Table 4) On multiple logistic regression analysis the only factors 
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predictive of mortality were HIV (OR=2.081; 95%CI 1.651-3.237), age ≥65years (OR=5.947; 95%CI3.581-17.643), and 




Pneumococci are major contributors to community acquired pneumonia and mortality worldwide; however, more 
knowledge is needed, especially in developing countries like Nigeria Where data is lacking. In this cohort study we 
described the epidemiology, associated co-morbidities and outcome of community acquired pneumococcal pneumonia as 
seen in a tertiary hospital in North-western Nigeria. The large sample size of 125 obtained over a two-year period including 
only microbiologically confirmed pneumococcal CAP argues in favor of the strength of our study.  
The peak age group affected and overall male preponderance observed in this study is in keeping with most studies 
on CAP in Nigeria were pneumococcus was the major pathogen (Macfarlane et al., 1979; Nwosu et al., 1991; Musa et al., 
2008). However, we found a slight peak among females within the reproductive age group. This could be attributed to the 
close proximity of these cohorts to children, whom in many studies were shown to act as reservoirs for adult infection 
(Hoshino et al., 2002; Muhlemann et al., 2003).    
Pneumococcal pneumonia occurred preferentially during the cold dry season This phenomenon has already been 
described, with a clear link to external temperature (Dowell et al., 2003) which results in drying of mucosal surfaces, 
coupled with concomitant respiratory viral infections (Talbot et al., 2005a) and increased tendency to cytoadherence by 
bacteria (Hakansson et al., 1994). The number of patients seen in this study was higher during the harmattan and dry season 
with fewer cases seen during the rainy season. This seasonal variation is similar to what was reported by Macfarlen et al. 
(1979) in the 70s and Onyemelukwe et al. (1982) in the 80s in Zaria, Nigeria. 
Although it is a hospital based study, high rate of HIV infection (11.5%) was observed among the patients studied 
when compared with Nigerian prevalence of 5% (WHO, 2009). Previous studies have shown high rate of pneumococcal 
infection among HIV infected patients (Gilks et al., 1996; Redd et al., 1990; Garcia-Leoni et al., 1992; Schuchat et al., 
1991). In fact HIV infection has been recognized as a risk factor for recurrent IPI (Nuorti et al., 2000; Turett et al., 2001).  
 
The comorbidities identified in our study were also reported to be risk factors for pneumococcal disease in several 
studies worldwide (Janoff et al., 1993; Gentile et al., 2003; Laupland et al., 2004; Talbot et al., 2005b; Lipsky et al., 1986; 
Chi et al., 2006).  The number of patients with COPD in this study outnumbered that of smokers (a major risk factor), this 
is not surprising as  studies in Nigeria has identified in-door pollution such as  the use of fire wood for cooking as a 
significant risk factor for COPD (Erhabo et al., 2002), which could have accounted for the difference. Other common risk 
factors were not seen in this study, probably because of the limited sample size and restriction of the study to medical wards 
as this would have missed out some solid malignancies admitted in to surgical oncology unit. 
Studies have reported that the risk of dying in patients with pneumococcal disease is dependent on host factors 
such as age and comorbidities as well as bacterial factors such as serotype and antibiotic resistance (Alanee et al., 2007; 
Harboe et al., 2009; Jansen et al., 2009; Weinberger et al., 2010). In the current study HIV, age ≥ 65 and CURB-65 score of 
≥ 3 were shown to be independent risk factors for mortality, indicating that these patient groups are important vaccination 
targets in Nigeria for reducing mortality associated with pneumococcal infection. In a multivariate model, 
immunosuppression (Klemets et al., 2008) was also shown to increase mortality risk in patients with pneumococcal 
pneumonia. Gordon et al. (2002) showed HIV infected African patients to have higher mortality following pneumococcal 
infection. In addition to being at higher absolute risk for pneumococcal infection, older adults are also at much higher risk 
for death should they acquire the infection_(Yu et al., 2003). This may be related to ageing related changes in both the 
innate and adaptive immune response (De Gaudio et al., 2009).
 
In a recent study, age-related impairment of alveolar 
macrophages and Toll-like receptor levels were seen in mice with pneumonia caused by pneumococcus (Boyd et al., 2012). 
It is also known that; ageing is associated with a procoagulant state and mitochondrial damage resulting in cellular 
apoptosis during sepsis (Gavazzi and Krause, 2002). This is reflected in our study, where age ≥65years was the strongest 
predictor of mortality in a logistic regression model.  
The extensive use, misuse and abuse of antibiotics have been said to be the main driving factors of drug resistance 
in developing countries of world, where access to drugs are poorly controlled and the level of self-medication remains high 
(Arikpo et al., 2011). Hence it is not surprising we found resistance to antibiotics which are commonly used as first line 
empirical treatment for pneumonia in Nigeria. A similar trend has been reported in previous studies in Nigeria (Habib et al., 
2003; Akanbi et al., 2004; Iwalokun et al., 2012; Adeleye et al., 2008). The prophylactic usage TMP/SMX in AIDS patients 
has been linked to the wide spread pneumococcal resistance to TMP/SMX (Soeters et al., 2012). However, this antibiotic 
had been recommended by theWHO (WHO, 2005) for the treatment of pneumococcal disease in HIV/AIDS patients. The 
resistance rate to TMP/SMX in this study is alarming and this has implication on the use of this drug as prophylaxis for 
pneumococcal infection in HIV/AIDS patients in Nigeria. 
Our case definition for pneumococcal pneumonia was limited to clinical findings, chest x ray features and isolation 
of pneumococcus from an ideal sputum specimen, rather than the gold standard lung aspirate, hence our data might not 
have described true invasive pneumococcal pneumonia. This is due to lack of the expertise in doing the procedure and 
restriction in our ethical approval. Our study highlighted the significance of pneumococcus as a leading cause of 
community acquired pneumonia in North-western Nigeria. With available effective pneumococcal vaccines, effort should 
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be geared towards popularizing vaccinating at-risk adult particularly those above 65years of age in Nigeria. Measures to 
curtail the emergence and spread of pneumococcal resistance such as antibiotic policy and introduction of antimicrobial 
stewardship program need to be implemented.  
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